ANIX
Anixa Biosciences, Inc.
Price Chart
Latest Quote
$2.48
-0.14 (-5.34%)
Current Price
| Previous Close | $2.62 |
| Open | $2.62 |
| Day High | $2.64 |
| Day Low | $2.45 |
| Volume | 106,659 |
Stock Information
| Shares Outstanding | 33.53M |
| Total Debt | $193K |
| Cash Equivalents | $14.20M |
| Net Income | $-10.31M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $83.15M |
| EPS (TTM) | $-0.32 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $67.91M |
| Income | $-10.31M |
| Book/sh | $0.45 |
| Cash/sh | $0.42 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 11.49 |
| Current Ratio | 12.18 |
| Debt/Eq | 1.39 |
Returns & Margins
| ROA | -40.39% |
| ROE | -68.06% |
Ownership
| Insider Ownership | 5.38% |
| Institutional Ownership | 15.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.89 |
| PEG | -0.11 |
| P/B | 5.50 |
Analyst Data
| Recommendation | none |
| Target Price | $11.00 |
Technical Indicators
| SMA20 | $2.75 |
| SMA50 | $2.81 |
| SMA200 | $3.32 |
| RSI | 30.68 |
| ATR | 0.1400 |
| Shares Float | 31.72M |
| Short Float | 3.10% |
| Short Ratio | 8.35 |
| Volatility | 0.60 |
| Rel Volume | 1.02 |
Performance History
| Week | -8.15% |
| Month | -18.95% |
| Quarter | -12.98% |
| 6 Months | -48.87% |
| YTD | -21.52% |
| Year | -11.11% |
| 3 Years | -18.95% |
| 5 Years | -37.53% |
| 10 Years | -25.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $2.48 | 110,200 |
| 2026-06-04 | $2.62 | 92,300 |
| 2026-06-03 | $2.52 | 89,600 |
| 2026-06-02 | $2.55 | 248,200 |
| 2026-06-01 | $2.70 | 139,500 |
| 2026-05-29 | $2.70 | 93,700 |
| 2026-05-28 | $2.70 | 127,100 |
| 2026-05-27 | $2.65 | 68,600 |
| 2026-05-26 | $2.73 | 104,600 |
| 2026-05-22 | $2.79 | 40,500 |
| 2026-05-21 | $2.75 | 80,600 |
| 2026-05-20 | $2.73 | 115,200 |
| 2026-05-19 | $2.67 | 101,800 |
| 2026-05-18 | $2.76 | 118,300 |
| 2026-05-15 | $2.82 | 110,400 |
| 2026-05-14 | $2.89 | 101,200 |
| 2026-05-13 | $2.90 | 98,600 |
| 2026-05-12 | $2.95 | 109,000 |
| 2026-05-11 | $3.03 | 125,900 |
| 2026-05-08 | $3.00 | 77,100 |
| 2026-05-07 | $2.96 | 115,600 |
| 2026-05-06 | $3.06 | 101,300 |
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
đ° Latest News
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference
MarketBeat âĸ 2026-04-15T02:02:04Z
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress
MarketBeat âĸ 2026-03-13T20:45:38Z
Anixa Biosciences CEO Calls 2026 âPivotalâ as Breast Cancer Vaccine, Ovarian CAR-T Advance
MarketBeat âĸ 2026-02-10T20:50:02Z
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Simply Wall St. âĸ 2026-02-08T12:42:23Z
Top Penny Stocks To Watch In November 2025
Simply Wall St. âĸ 2025-11-13T18:05:26Z
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-11-05T14:40:02Z
Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice
Zacks âĸ 2025-10-17T16:00:02Z
October 2025 Penny Stocks With Promising Potential
Simply Wall St. âĸ 2025-10-15T18:04:55Z
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Zacks âĸ 2025-10-02T13:40:02Z
September 2025's Promising Penny Stocks To Watch
Simply Wall St. âĸ 2025-09-16T18:05:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $210,000 | $0 |
| Operating Revenue | $0 | $0 | $210,000 | $0 |
| Reconciled Cost Of Revenue | - | $0 | $161,000 | $0 |
| Cost Of Revenue | - | $0 | $161,000 | $0 |
| Expenses | ||||
| Total Expenses | $11,701,000 | $13,831,000 | $11,221,000 | $13,875,000 |
| Net Non Operating Interest Income Expense | $673,000 | $1,133,000 | $1,081,000 | $104,000 |
| Operating Expense | $11,701,000 | $13,831,000 | $11,060,000 | $13,875,000 |
| General And Administrative Expense | $6,630,000 | $7,435,000 | $6,291,000 | $7,172,000 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,927,000 | $-12,554,000 | $-9,811,000 | $-13,595,000 |
| Net Interest Income | $673,000 | $1,133,000 | $1,081,000 | $104,000 |
| Interest Income | $673,000 | $1,133,000 | $1,081,000 | $104,000 |
| Normalized Income | $-10,927,000 | $-12,554,000 | $-9,811,000 | $-13,595,000 |
| Net Income From Continuing And Discontinued Operation | $-10,927,000 | $-12,554,000 | $-9,811,000 | $-13,595,000 |
| Total Operating Income As Reported | $-11,701,000 | $-13,831,000 | $-11,011,000 | $-13,875,000 |
| Net Income Common Stockholders | $-10,927,000 | $-12,554,000 | $-9,811,000 | $-13,595,000 |
| Net Income | $-10,927,000 | $-12,554,000 | $-9,811,000 | $-13,595,000 |
| Net Income Including Noncontrolling Interests | $-11,028,000 | $-12,698,000 | $-9,930,000 | $-13,771,000 |
| Net Income Continuous Operations | $-11,028,000 | $-12,698,000 | $-9,930,000 | $-13,771,000 |
| Pretax Income | $-11,028,000 | $-12,698,000 | $-9,930,000 | $-13,771,000 |
| Interest Income Non Operating | $673,000 | $1,133,000 | $1,081,000 | $104,000 |
| Operating Income | $-11,701,000 | $-13,831,000 | $-11,011,000 | $-13,875,000 |
| Gross Profit | - | $0 | $49,000 | $0 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.34 | $-0.39 | $-0.32 | $-0.45 |
| Basic EPS | $-0.34 | $-0.39 | $-0.32 | $-0.45 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,665,000 | $-13,794,000 | $-10,965,000 | $-13,833,000 |
| Reconciled Depreciation | $36,000 | $37,000 | $46,000 | $42,000 |
| EBITDA (Bullshit earnings) | $-11,665,000 | $-13,794,000 | $-10,965,000 | $-13,833,000 |
| EBIT | $-11,701,000 | $-13,831,000 | $-11,011,000 | $-13,875,000 |
| Diluted Average Shares | $32,454,000 | $31,898,000 | $30,980,000 | $30,374,000 |
| Basic Average Shares | $32,454,000 | $31,898,000 | $30,980,000 | $30,374,000 |
| Diluted NI Availto Com Stockholders | $-10,927,000 | $-12,554,000 | $-9,811,000 | $-13,595,000 |
| Minority Interests | $101,000 | $144,000 | $119,000 | $176,000 |
| Research And Development | $5,071,000 | $6,396,000 | $4,769,000 | $6,703,000 |
| Selling General And Administration | $6,630,000 | $7,435,000 | $6,291,000 | $7,172,000 |
| Other Gand A | $6,630,000 | $7,435,000 | $6,291,000 | $7,172,000 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-05-31
Balance Sheet (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,161,000 | $19,998,000 | $24,337,000 | $29,047,000 |
| Total Assets | $16,080,000 | $21,591,000 | $25,522,000 | $30,412,000 |
| Total Non Current Assets | $193,000 | $229,000 | $166,000 | $212,000 |
| Current Assets | $15,887,000 | $21,362,000 | $25,356,000 | $30,200,000 |
| Other Current Assets | $713,000 | $1,265,000 | $1,242,000 | $467,000 |
| Receivables | $0 | $173,000 | $270,000 | $46,000 |
| Accounts Receivable | $0 | $173,000 | $270,000 | $46,000 |
| Cash Cash Equivalents And Short Term Investments | $15,174,000 | $19,924,000 | $23,844,000 | $29,687,000 |
| Cash And Cash Equivalents | $1,244,000 | $1,271,000 | $915,000 | $12,360,000 |
| Prepaid Assets | - | - | - | $513,000 |
| Debt | ||||
| Total Debt | $204,000 | $232,000 | $175,000 | $221,000 |
| Long Term Debt And Capital Lease Obligation | $163,000 | $203,000 | $123,000 | $175,000 |
| Current Debt And Capital Lease Obligation | $41,000 | $29,000 | $52,000 | $46,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,130,000 | $2,703,000 | $2,151,000 | $2,212,000 |
| Total Non Current Liabilities Net Minority Interest | $163,000 | $203,000 | $123,000 | $175,000 |
| Current Liabilities | $1,967,000 | $2,500,000 | $2,028,000 | $2,037,000 |
| Payables And Accrued Expenses | $1,926,000 | $2,471,000 | $1,976,000 | $1,991,000 |
| Payables | $165,000 | $525,000 | $206,000 | $265,000 |
| Accounts Payable | $165,000 | $525,000 | $206,000 | $265,000 |
| Equity | ||||
| Common Stock Equity | $15,161,000 | $19,998,000 | $24,337,000 | $29,047,000 |
| Total Equity Gross Minority Interest | $13,950,000 | $18,888,000 | $23,371,000 | $28,200,000 |
| Stockholders Equity | $15,161,000 | $19,998,000 | $24,337,000 | $29,047,000 |
| Retained Earnings | $-251,677,000 | $-240,750,000 | $-228,196,000 | $-218,385,000 |
| Other | ||||
| Ordinary Shares Number | $33,013,829 | $32,196,862 | $31,145,219 | $30,913,902 |
| Share Issued | $33,013,829 | $32,196,862 | $31,145,219 | $30,913,902 |
| Tangible Book Value | $15,161,000 | $19,998,000 | $24,337,000 | $29,047,000 |
| Invested Capital | $15,161,000 | $19,998,000 | $24,337,000 | $29,047,000 |
| Working Capital | $13,920,000 | $18,862,000 | $23,328,000 | $28,163,000 |
| Capital Lease Obligations | $204,000 | $232,000 | $175,000 | $221,000 |
| Total Capitalization | $15,161,000 | $19,998,000 | $24,337,000 | $29,047,000 |
| Minority Interest | $-1,211,000 | $-1,110,000 | $-966,000 | $-847,000 |
| Treasury Stock | $0 | $6,000 | $0 | - |
| Additional Paid In Capital | $266,508,000 | $260,432,000 | $252,222,000 | $247,123,000 |
| Capital Stock | $330,000 | $322,000 | $311,000 | $309,000 |
| Common Stock | $330,000 | $322,000 | $311,000 | $309,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $163,000 | $203,000 | $123,000 | $175,000 |
| Current Capital Lease Obligation | $41,000 | $29,000 | $52,000 | $46,000 |
| Current Accrued Expenses | $1,761,000 | $1,946,000 | $1,770,000 | $1,726,000 |
| Net PPE | $193,000 | $229,000 | $166,000 | $212,000 |
| Gross PPE | $193,000 | $229,000 | $166,000 | $212,000 |
| Leases | $193,000 | $229,000 | $166,000 | $212,000 |
| Buildings And Improvements | $193,000 | $229,000 | $166,000 | $212,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $13,930,000 | $18,653,000 | $22,929,000 | $17,327,000 |
Fetched: 2026-05-31
Cash Flow Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,173,000 | $-7,335,000 | $-6,209,000 | $-6,492,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,173,000 | $-7,335,000 | $-6,209,000 | $-6,492,000 |
| Cash Flow From Continuing Operating Activities | $-7,173,000 | $-7,335,000 | $-6,209,000 | $-6,492,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $4,866,000 | $4,276,000 | $-5,602,000 | $-10,728,000 |
| Cash Flow From Continuing Investing Activities | $4,866,000 | $4,276,000 | $-5,602,000 | $-10,728,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-6,000 | $0 | - |
| Issuance Of Capital Stock | $2,378,000 | $2,955,000 | $0 | $0 |
| Financing Cash Flow | $2,280,000 | $3,415,000 | $366,000 | $452,000 |
| Cash Flow From Continuing Financing Activities | $2,280,000 | $3,415,000 | $366,000 | $452,000 |
| Net Common Stock Issuance | $2,378,000 | $2,949,000 | $0 | $0 |
| Common Stock Issuance | $2,378,000 | $2,955,000 | $0 | $0 |
| Other | ||||
| End Cash Position | $1,244,000 | $1,271,000 | $915,000 | $12,360,000 |
| Beginning Cash Position | $1,271,000 | $915,000 | $12,360,000 | $29,128,000 |
| Changes In Cash | $-27,000 | $356,000 | $-11,445,000 | $-16,768,000 |
| Proceeds From Stock Option Exercised | $-98,000 | $466,000 | $366,000 | $452,000 |
| Common Stock Payments | $0 | $-6,000 | $0 | - |
| Net Investment Purchase And Sale | $4,866,000 | $4,276,000 | $-5,602,000 | $-10,728,000 |
| Sale Of Investment | $49,226,000 | $68,046,000 | $38,809,000 | $11,758,000 |
| Purchase Of Investment | $-44,360,000 | $-63,770,000 | $-44,411,000 | $-22,486,000 |
| Change In Working Capital | $152,000 | $526,000 | $-1,060,000 | $485,000 |
| Change In Other Current Liabilities | $-28,000 | $-43,000 | $-46,000 | $-38,000 |
| Change In Payables And Accrued Expense | $-545,000 | $495,000 | $-15,000 | $760,000 |
| Change In Accrued Expense | $-185,000 | $176,000 | $44,000 | $631,000 |
| Change In Payable | $-360,000 | $319,000 | $-59,000 | $129,000 |
| Change In Account Payable | $-360,000 | $319,000 | $-59,000 | $129,000 |
| Change In Prepaid Assets | $552,000 | $-23,000 | $-775,000 | $-208,000 |
| Change In Receivables | $173,000 | $97,000 | $-224,000 | $-29,000 |
| Other Non Cash Items | $129,000 | $380,000 | $313,000 | $752,000 |
| Stock Based Compensation | $3,681,000 | $4,420,000 | $4,422,000 | $6,000,000 |
| Amortization Of Securities | $-143,000 | $0 | - | - |
| Depreciation Amortization Depletion | $36,000 | $37,000 | $46,000 | $42,000 |
| Depreciation And Amortization | $36,000 | $37,000 | $46,000 | $42,000 |
| Depreciation | $36,000 | $37,000 | $46,000 | $42,000 |
| Net Income From Continuing Operations | $-11,028,000 | $-12,698,000 | $-9,930,000 | $-13,771,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Sale Of PPE | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Purchase Of PPE | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-05-31